These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 29719928

  • 1. Long-term follow-up of 2 patients treated with 90 Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma.
    Golstein SC, Muylle K, Vercruyssen M, Spilleboudt C, de Wind A, Bron D.
    Eur J Haematol; 2018 Sep; 101(3):415-417. PubMed ID: 29719928
    [Abstract] [Full Text] [Related]

  • 2. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
    Schnell R, Dietlein M, Schomäcker K, Kobe C, Borchmann P, Schicha H, Hallek M, Engert A.
    Onkologie; 2008 Feb; 31(1-2):49-51. PubMed ID: 18268399
    [Abstract] [Full Text] [Related]

  • 3. Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
    Mocikova H, Pytlik R, Stepankova P, Michalka J, Markova J, Koren J, Buresova L, Raida L, Kral Z.
    Acta Haematol; 2015 Feb; 134(3):187-92. PubMed ID: 26021284
    [Abstract] [Full Text] [Related]

  • 4. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
    Spinner MA, Varma G, Advani RH.
    Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
    [Abstract] [Full Text] [Related]

  • 5. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
    Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M.
    Blood; 2008 Jan 01; 111(1):109-11. PubMed ID: 17938252
    [Abstract] [Full Text] [Related]

  • 6. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
    Eichenauer DA, Plütschow A, Schröder L, Fuchs M, Böll B, von Tresckow B, Diehl V, Borchmann P, Engert A.
    Blood; 2018 Oct 04; 132(14):1519-1525. PubMed ID: 30064977
    [Abstract] [Full Text] [Related]

  • 7. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA.
    J Clin Oncol; 2002 May 15; 20(10):2453-63. PubMed ID: 12011122
    [Abstract] [Full Text] [Related]

  • 8. SOHO State of the Art Updates and Next Questions |Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
    Binkley MS, Advani RH.
    Clin Lymphoma Myeloma Leuk; 2023 Jul 15; 23(7):471-476. PubMed ID: 37076366
    [Abstract] [Full Text] [Related]

  • 9. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.
    Strobbe L, Valke LL, Diets IJ, van den Brand M, Aben K, Raemaekers JM, Hebeda KM, van Krieken JH.
    Ann Hematol; 2016 Feb 15; 95(3):417-23. PubMed ID: 26732883
    [Abstract] [Full Text] [Related]

  • 10. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
    Illés A, Simon Z, Tóth E, Rosta A, Miltényi Z, Molnár Z.
    Pathol Oncol Res; 2008 Dec 15; 14(4):411-21. PubMed ID: 18431694
    [Abstract] [Full Text] [Related]

  • 11. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma.
    Hartmann S, Plütschow A, Mottok A, Bernd HW, Feller AC, Ott G, Cogliatti S, Fend F, Quintanilla-Martinez L, Stein H, Klapper W, Möller P, Rosenwald A, Engert A, Hansmann ML, Eichenauer DA.
    Am J Hematol; 2019 Nov 15; 94(11):1208-1213. PubMed ID: 31396979
    [Abstract] [Full Text] [Related]

  • 12. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA.
    J Nucl Med; 2003 Mar 15; 44(3):465-74. PubMed ID: 12621016
    [Abstract] [Full Text] [Related]

  • 13. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
    Eichenauer DA, Plütschow A, Fuchs M, von Tresckow B, Böll B, Behringer K, Diehl V, Eich HT, Borchmann P, Engert A.
    J Clin Oncol; 2015 Sep 10; 33(26):2857-62. PubMed ID: 26240235
    [Abstract] [Full Text] [Related]

  • 14. How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
    Eichenauer DA, Engert A.
    Blood; 2020 Dec 24; 136(26):2987-2993. PubMed ID: 32877522
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Nodular lymphocyte-predominant Hodgkin's lymphoma: Principles of diagnosis and treatment].
    Moiseeva TN, Al-Radi LS, Kovrigina AM, Goryacheva SR, Julakyan UL, Margolin OV, Skidan NI, Tseytlina MA, Kravchenko SK.
    Ter Arkh; 2015 Dec 24; 87(11):78-83. PubMed ID: 26821421
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG.
    Binkley MS, Rauf MS, Milgrom SA, Pinnix CC, Tsang R, Dickinson M, Ng AK, Roberts KB, Gao S, Balogh A, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras JP, Wright C, Kelsey CR, Brady JL, Mikhaeel NG, Hoppe BS, Terezakis SA, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig JL, Jackson C, Song E, Sehgal S, Advani RH, Natkunam Y, Constine LS, Eich HT, Wirth A, Hoppe RT.
    Blood; 2020 Jun 25; 135(26):2365-2374. PubMed ID: 32211877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.